Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer

Lüftner D, Lux MP, Fehm TN, Welslau M, Müller V, Schütz F, Fasching P, Janni W, Thomssen C, Witzel I, Beierlein M, Belleville E, Untch M, Thill M, Ditsch N, Aktas B, Banys-Paluchowski M, Kolberg-Liedtke C, Wöckel A, Kolberg HC, Harbeck N, Stickeler E, Tesch H, Hartkopf AD (2023)

Publication Type: Journal article, Review article

Publication year: 2023

Journal

Book Volume: 83

Pages Range: 299-309

Journal Issue: 3

DOI: 10.1055/a-2018-9184

Abstract

Large-scale study programs on CDK4/6 inhibitors, targeted therapies, and antibody-drug conjugates launched in recent years have yielded results from current studies which are now being published in journals and presented at international conferences. In this context, new results are available from the major CDK4/6 inhibitor studies. Also, an increasing amount of data is being published from large-scale genomic studies on efficacy and resistance mechanisms in patients treated with CDK4/6 inhibitors. These results now form the basis for further research plans to investigate combination therapies and treatment sequencing. Based on the latest published results, sacituzumab govitecan is now available as a second antibody-drug conjugate; this brings an advantage in terms of overall survival for patients with hormone receptor-positive (HRpos)/HER2-negative (HER2neg) breast cancer. In this review article, we summarize the latest developments and place them in context according to the current status of research.

Authors with CRIS profile

Involved external institutions

Universitätsklinikum Düsseldorf Germany (DE) Diakonissen-Stiftungs-Krankenhaus Speyer Germany (DE) St. Vincenz-Krankenhaus Germany (DE) Universitätsklinikum Hamburg-Eppendorf (UKE) Germany (DE) Immanuel Klinik Märkische Schweiz Germany (DE) Agaplesion Markus Krankenhaus Germany (DE) Universitätsklinikum Ulm Germany (DE) HELIOS Kliniken Germany (DE) Martin-Luther-Universität Halle-Wittenberg (MLU) Germany (DE) Universitätsklinikum Würzburg Germany (DE) Universitätsklinikum Essen Germany (DE) Universitätsklinikum Augsburg Germany (DE) Universität Leipzig Germany (DE) Marienhospital Bottrop Germany (DE) Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) Germany (DE) ClinSol GmbH & Co.KG Germany (DE) Klinikum der Universität München Germany (DE)

How to cite

APA:

Lüftner, D., Lux, M.P., Fehm, T.N., Welslau, M., Müller, V., Schütz, F.,... Hartkopf, A.D. (2023). Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer. Geburtshilfe und Frauenheilkunde, 83(3), 299-309. https://doi.org/10.1055/a-2018-9184

MLA:

Lüftner, Diana, et al. "Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer." Geburtshilfe und Frauenheilkunde 83.3 (2023): 299-309.

BibTeX: Download